Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, Thaventhiran JED, Toshner M
,
et al
No abstract available
Keywords:

3207 Medical Microbiology

,

32 Biomedical and Clinical Sciences

,

31 Biological Sciences

,

3204 Immunology

,

Vaccine Related

,

Genetics

,

Infectious Diseases

,

Biotechnology

,

Coronaviruses

,

Emerging Infectious Diseases

,

Coronaviruses Vaccines

,

Prevention

,

Immunization

,

Infection

,

3 Good Health and Well Being

,

Aged

,

Aged, 80 and over

,

Angiotensin-Converting Enzyme 2

,

Antibodies, Monoclonal

,

Antibodies, Neutralizing

,

Antibodies, Viral

,

COVID-19

,

COVID-19 Vaccines

,

Female

,

HEK293 Cells

,

Humans

,

Immune Evasion

,

Immunization, Passive

,

Male

,

Middle Aged

,

Models, Molecular

,

Mutation

,

Neutralization Tests

,

SARS-CoV-2

,

Spike Glycoprotein, Coronavirus

,

Vaccines, Synthetic

,

COVID-19 Serotherapy

,

mRNA Vaccines